Therakind enters exclusive distribution partnership with aVIPharma
Launch of Jylamvo in Greece
28 February 2019 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, has entered into an exclusive distribution agreement with a V.I. Pharma International S.A. (“aVIPharma ”) for Therakind’s lead product, Jylamvo.
Under this agreement, aVIPharma secures exclusive rights to market, commercialise and sell Jylamvo in Greece. Jylamvo is already available in the UK.
Jylamvo is a novel methotrexate 2mg/ml Oral Solution which is licensed for use in adults and children over three years old for the treatment of rheumatological disorders (adult and juvenile) and adult psoriasis and psoriatic arthritis, and for the maintenance treatment of acute lymphoblastic leukaemia (ALL). Jylamvo has a marketing authorization which allows it to be sold throughout the European Economic Area and is the first oral liquid formulation of methotrexate to be authorised in Europe for the treatment of polyarthritic juvenile idiopathic arthritis (JIA).
Jylamvo as an oral liquid is easier for patients with swallowing difficulties to take than tablets and its use eliminates dosing inaccuracies and unnecessary exposure to the cytotoxic methotrexate powder which may occur if tablets are crushed. As a licensed oral liquid, Jylamvo has proven stability and no inappropriate excipients which may be the case with unlicensed oral liquids. Jylamvo also has a palatable orange taste which masks methotrexate’s bitter taste. It also addresses compliance issues which may occur with methotrexate injections due to patients’ fear of needles and intolerance of injection site pain and reaction.
Dr Susan Conroy, CEO of Therakind, said:
“Following the approval by the EMA in 2017, we are now focused on building out our distribution network to increase access to Jylamvo for our patients. aVIPharma has a strong market presence in Greece and we looking to building this partnership to provide age-specific medicines for all.”
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Notes to Editors
About a V.I. Pharma
A V.I. Pharma’s mission is to promote and deliver technologically advanced pharmaceutical products to patients who constitute “valuable rarities” need specific antidotes against the toxicity of the treatment received. its vision is to provide patients with access to standard technology-based therapies that serve personalized treatment and care.
